Several phase III studies (Quilty et al, 1982; Lewington et al, 1991; McEwan et al, 1994; Malmberg et al, 1997) now support the usefulness and cost effectiveness of Sr-89 either as an alternative or an adjunct to external beam radiotherapy (EBRT) in men with bone pain due to metastatic prostate cancer. Primary study end points have included pain response presented in terms of reduction in severity and/or frequency of pain and/or analgesic use, delayed onset of new painful sites and/or decrease in EBRT requirement over the patient's remaining lifetime.
Following the establishment of a Government reimbursement in early 1995, Sr-89 therapy for the relief of bone pain due to prostate cancer became widely available in Australia. A group of interested Radiation Oncologists (the Australian Metastron User's Group) took this opportunity to initiate a prospective study to (1) confirm that treatment efficacy and toxicity were consistent with the world literature and to (2) simultaneously assess the nature and time course of any possible QoL benefits using a validated instrument. Secondary end-points included toxicity, (specifically bone marrow depression, pain 'flare' and/or other unexpected morbidity), and PSA 'response' following Sr-89.
MATERIALS AND METHODS
This was a prospective multicentre study involving 13 oncology centres in 5 states and territories of Australia. Accrual took place over a two-year period from mid 1995 to mid 1997. There was a minimum 8-month interval from the date of Sr-89 injection in the last study patient to analysis, with a median follow up overall of 6.8 months (censoring patients at death).
Eligible patients were those who had histologically proven prostate cancer with bone scan evidence of metastatic disease and who had progressed either clinically, biochemically or both following 'standard' first-line hormone therapy (with or without further hormonal manoeuvres), and who had one or more sites of bony pain. 7 patients had previously been treated with various chemotherapy agents as well.
The protocol deliberately did not specify the exact indication for the use of Sr-89 so as to reflect general clinical practice. However, Sr-89 was not approved at that time for use as an adjunct to external beam radiotherapy or for men with asymptomatic bone Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer metastases only. Patients were required to have platelet levels ≥100 × 10 9 l -1 and white cell counts ≥3.5 × 10 9 l -1 prior to delivery of Sr-89. Ethics committee approval was granted by involved institutions and patients were required to provide written consent.
At registration, baseline QoL and pain evaluations were undertaken. QoL was measured using the University of Manitoba, Winnipeg, Functional Living Index -Cancer Instrument (FLIC), Schipper, 1987 . This is a well-validated, easily applied self-assessment questionnaire incorporating multiple facets of psychosocial state and sociability as well as parameters of physical well being (Appendix B). Furthermore, this instrument was of particular interest in that the validation studies of FLIC report lack of correlation between traditional assessments of response, for example improvement in pain, and other areas impacting on day-to-day function such as mood and relationships with others.
Pain was assessed jointly by physician and patient according to the Radiation Therapy Oncology Group (RTOG) criteria (Appendix A), (Tong et al, 1982) . Analgesic requirements prior to and after delivery of Sr-89 were recorded and used in conjunction with pain scores to establish pain response over the time intervals examined. Patients who had increase in analgesic requirements were not scored as having pain improvement, regardless of RTOG pain score status.
Other baseline parameters including performance status, PSA at recruitment, time since diagnosis of metastases, and extent of skeletal disease (greater or less than 20 bone scan 'hot spots') were recorded to allow correlation of these measures of disease status at time of Sr-89 therapy with QoL responses. It was hypothesized that patients who were earlier in the course of their metastatic disease and/or with better performance status might benefit more from Sr-89 than those who were not. In addition, it was postulated that biochemical (PSA) changes, if still a useful surrogate for disease activity in advanced disease, might parallel pain response.
Patients received a single 150 MBq intravenous dose of Sr-89. Follow up assessments of pain and QoL were conducted at between two and three weeks following the injection and then monthly if possible, until death. Toxicity, using WHO/EORTC criteria for bone marrow suppression (Miller et al, 1981) and PSA data were also recorded on these occasions. Where monthly visits to the clinic were deemed inappropriate either on geographic or medical grounds, then some information was collected by mailed FLIC questionnaires and telephone conversations with patients or carers.
One patient was lost to follow up at the time of analysis. 8 patients had no post-treatment pain scores recorded (4) or response data was only available beyond 3 months after Sr-89 (4). 11 patients had no follow-up QoL data collected. This left 85 patients evaluable for pain response and 82 patients evaluable for QoL analysis.
The time intervals chosen for examination of QoL and pain response were 0 to 6 weeks from Sr-89 (as any beneficial effect of treatment would be expected to be seen well within this period), 6 weeks to 3 months (as most investigators report this as a median period for maintaining pain response to radionuclide treatment) and from 3 months to the time of death. The number of surviving patients in the last time interval was too small to meaningfully report results.
Time to event (death) was measured from the day of the Sr-89 injection, with survival curves calculated using the method of Kaplan and Meier (1958) . For the follow up periods of 0 to 6 weeks and 6 weeks to 3 months, patients with multiple QoL measures had their QoL scores averaged within individuals. Factors considered as potentially influencing QoL changes included ECOG performance status, number of hot spots and PSA at baseline, as well as time from diagnosis of bone metastases and pain response to therapy. Univariate and multivariate comparisons were performed on these parameters using multiple linear regression and where appropriate multiple logistic regression analysis.
RESULTS

Pain response
Pain response to Sr-89 was categorized as complete, moderate or minimal according to the RTOG pain scoring criteria (Appendix A). Overall pain response (any reduction in RTOG pain score) over the first 6 week and 6 week to 3 month periods taken together was 53 (62.4%) of 85 evaluable men. The degree of response is recorded in Table 1 . Complete relief of pain (no analgesics required) was reported by 15 men (17.6%).
Quality of life analysis
The FLIC index was observed to increase by a median of 2.3 points in 61 evaluable patients over the first time period and 12.8 points from baseline in 55 evaluable patients in the second time interval (6 weeks to 3 months). Examination of the possible influence of known prognostic factors is presented in the forest plots in Figure 1 . None of these 'early metastatic disease' parameters nor performance status were found to statistically significantly relate to better QoL gain.
Patients achieving any pain response (minimal, moderate or complete) were statistically significantly more likely to have improvement in QoL on linear regression analysis (P = 0.013). This relationship was sustained in a multivariate analysis adjusting for factors that might confound changes in QoL index such as measures of more advanced disease, as described, and poor performance status (P = 0.004).
Toxicity
In accordance with other investigators, pain 'flare' was defined as a temporary increase in pain following injection of radionuclide occurring between 0 and 14 days after the injection and lasting for between 1 and 14 days. 35 out of 90 evaluable patients (39%) had a flare, the majority occurring between 1 and 3 days following Sr-89 and lasting for 2 to 5 days.
10 patients experienced bone marrow depression that presented a clinical problem. One of these patients had oesophageal ulceration which bled 3 weeks after Sr-89. 3 patients became tranfusiondependent and 7 others required at least one blood transfusion following Sr-89. Despite protocol stipulations and recommended guidelines for the use of this agent, only 49 patients (53%) had sequential white cell and platelet counts recorded following Sr-89. 6 of these (12% of evaluable patients) had post-treatment white cell counts of grade 2 or worse on at least one occasion. 11 patients (22% of evaluable patients) developed grade 2 or worse thrombocytopenia.
12 patients (13%) reported nausea and/or vomiting (10) or diarrhoea (2) which was felt by the treating physician and/ or patient to possibly be attributable to Sr-89. Gastrointestinal disturbance occurred between 0 days and 2 weeks after injection of Sr-89. Other adverse events included 7 cases of pathological fracture during the course of the patients' remaining lifetime. 10 patients developed malignant spinal cord compression (MSCC) at some time following injection of Sr-89. In none of these patients was MSCC known to be imminent at the time of Sr-89 -a contraindication to the use of bone-seeking radiopharmaceutical. In 6 of these men, MSCC occurred within three weeks of the injection. One patient developed an attack of gout 7 days following Sr-89.
PSA response
PSA 'responders' were defined according to the Trans Canada Study (Porter and McEvan, 1993) as being those in whom the PSA reduced at least 50% from the pre-treatment level. Depending on the time point examined, between 32 and 37% of evaluable men had PSA responses, thus defined, over 4 months following Sr-89, beyond which numbers of patients became too small to meaningfully analyse. PSA response seen in this study is presented in Figure 2 and is compared with the analogous Trans Canada results of both the active (400MBq Sr-89) and placebo arms. Numbers shown indicate the number of patients evaluable for assessment of PSA response at each time point.
Correlation of PSA responders and pain responders (of any degree), using a Chi-squared analysis did not find a statistically significant relationship between these two patient groups despite an initial trend (P values for 0 to 6 week and 6 week to 3 month intervals, 0.06 and 0.4 respectively).
There was no overall survival difference seen between men who had and those who did not have a PSA response.
DISCUSSION
The response rates to Sr-89 therapy of 62.5% (including 17.5% complete responses) in this group of patients were typical of those reported in phase III Porter et al, 1993a; Quilty et al, 1994) and large phase II studies (Robinson et al, 1989; Laing et al, 1991) in the literature. This is despite the relative 'late' use of this agent in this study as judged by the high median baseline PSA (96 ng ml -1 ), high proportion of patients with extensive skeletal disease (63% of 92 evaluable patients had more than 20 bone scan hot spots). Examination of the influence of prognostic factors on QoL score improvement (Figure 1 ) reveals some interesting trends. Whilst the confidence intervals are wide, the plots reveal that good prognosis patients (better ECOG, low baseline PSA and low bone scan load) tend to demonstrate larger increase in QoL score. This observation is in keeping with Laing et al (1991) who reported that a better analgesic effect was achieved with the administration of Sr-89 whilst skeletal disease load was relatively low. The trend for preferential benefit for good prognostic factors continued into the second period.
Although clinical experience and common sense suggest that QoL should improve in patients having reduction in pain, physical measures of response to therapies do not necessarily reflect their overall benefit to the patient. Demonstrating that QoL improvement really does accompany bone pain reduction following Sr-89 using objective testing is, therefore, important. In this study there was strong correlation with improved QoL for the first 6 weeks following Sr-89 therapy for patients in whom pain improved. This relationship remained highly statistically significant controlling for the above-mentioned indicators of more advanced metastatic disease and performance status.
The lack of demonstrable correlation between patients achieving pain responses and those in whom PSA reduced to 50% of its baseline level raises some points for contemplation. The exact mechanism of action of Sr-89 remains unknown but the results of this study would infer that the analgesic effect may be achieved through action on reactive bone cells around metastases or through effects mediated by other biological factors, rather than through direct cancer cell kill. Further, these findings suggest that either in this 'late' metastatic setting, PSA response is not a good surrogate of overall disease activity, or rather (and more likely), Sr-89 has a role in reduction of bone pain only without a substantial influence on the disease process as a whole.
On the other hand, the significant numbers of PSA 'responses' seen in this study, and in the Trans Canada Group report using Sr-89 at a higher dose, suggest that there is some cytotoxic or 'switching off' effect of Sr-89 on malignant prostate cells. This gives some support to the concept of a potential role for the earlier application of this radionuclide in the situation of subclinical or very early symptomatic metastatic disease, which was recently under investigation in Europe.
The toxicities recorded in this study point to the importance of pre-and post-treatment monitoring for patients receiving Sr-89, particularly in regard to bone marrow and neurological status.
In summary, this study suggests that we do improve metastatic prostate cancer patients' overall QoL with the use of Sr-89 when analgesic effect from this agent is achieved. As the current literature points to the advantage of early and adjunctive use of this agent in men with bone pain from prostate cancer metastases, it is beholden on clinicians treating these men to consider this therapy at the appropriate point in the time-course of their disease. 
